Related Experiment Video
Updated: Jun 23, 2026
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[Epidermal growth factor receptor and radiotherapy].
1Klinika onkologie a radioterapie, Fakultní nemocnice v Hradci Králové, LF UK, Hradec Králové. sirak@fnhk.cz
Summary
Inhibiting epidermal growth factor receptor (EGFR) may enhance radiotherapy for epithelial cancers by overcoming tumor resistance. This strategy targets EGFR
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Epidermal growth factor receptor (EGFR) is crucial for epithelial tissue regulation.
- Overexpressed EGFR drives epithelial carcinomas and confers radioresistance.
- EGFR promotes tumor cell survival and proliferation post-irradiation.
Purpose of the Study:
- To review the role of EGFR in healthy and cancerous tissues.
- To explore the relationship between EGFR and ionizing radiation response.
- To overview therapeutic strategies combining EGFR inhibition with radiotherapy.
Main Methods:
- Literature review of radiobiological studies.
- Analysis of preclinical and clinical data on EGFR inhibitors.
- Overview of EGFR function and modulation.
Main Results:
- EGFR signaling contributes to tumor radioresistance.
- EGFR inhibition can sensitize tumors to radiotherapy.
- Targeting EGFR may counteract radiation-induced tumor repopulation.
Conclusions:
- EGFR inhibition is a promising strategy for radiosensitizing epithelial cancers.
- Combining EGFR inhibitors with radiotherapy holds potential for improved cancer treatment.
- Further research into EGFR modulation in radiotherapy is warranted.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...